AR and prostate cancer: The first VHL-based PROTAC, targeting the androgen receptor (AR) in prostate cancer, was developed in 2012, while the first CRBN-based PROTAC, targeting BRD4, followed in 2015 (Bondeson et al., 2015; Lu et al., 2015).